PTK2 and central nervous system cancer: A small molecule inhibitor of N-acetylglucosaminyltransferase (MGAT5)[45], PST3.1a, can significantly inhibit the invasive and proliferative capacity of glioma by inhibiting the signaling of βR and FAK-related pathways, and in combination with TMZ can significantly prolong the survival of glioma patients[46].